Healthcare News | Neurology | AI & Healthcare Technology |
Neuralink Launches UK Clinical Trial to Test Brain Implants for Patients with Paralysis
Elon Musk’s brain implant company Neuralink announced on Thursday that it will launch a clinical study in the United Kingdom aimed at testing whether its brain-computer interface technology can enable people with severe paralysis to control digital and physical devices using only their thoughts.
The company is partnering with University College London Hospitals (UCLH) NHS Foundation Trust and Newcastle Hospitals NHS Foundation Trust to conduct the trial, according to a statement posted on X (formerly Twitter).
The study will recruit individuals living with paralysis caused by conditions such as spinal cord injuries or neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS). Participants will be implanted with Neuralink’s experimental device, which is designed to decode brain signals and transmit them wirelessly to external tools, including computers and robotic systems.
The UK trial marks Neuralink’s first foray into international clinical testing, following the launch of its initial human trials in the United States in 2024.
These trials began after the company addressed safety concerns raised by the U.S. Food and Drug Administration, which had initially rejected Neuralink’s application in 2022.
The company recently raised $650 million in its latest funding round, underscoring investor confidence in the potential of brain-computer interfaces (BCIs) to transform assistive technology and neurological care.
According to Neuralink, five patients with severe paralysis are currently using its implant in the U.S. to operate devices through thought alone, offering early signs of what could be a breakthrough in neurotechnology.
The UK clinical study is expected to begin patient recruitment later this year.
31 July 2025 | Neurolink Press | Neuralink’s first clinical study in Great Britain is open for recruitment
Disclaimer
This article is compiled from various resources researched and compiled by the contributor. It is in no way presented as an original work. Every effort has been made to correctly attribute quotes and content. Where possible all information has been independently verified. The Medical Education Network bears no responsibility for any inaccuracies which may occur from the use of third-party sources. If you have any queries regarding this article contact us
Fact-checking Policy
The Medical Education Network makes every effort to review and fact-check the articles used as source material in our summaries and original material. We have strict guidelines in relation to the publications we use as our source data, favouring peer-reviewed research wherever possible. Every effort is made to ensure that the information contained here is an accurate reflection of the original material. Should you find inaccuracies, out of date content or have any additional issues with our articles, please make use of the contact us form to notify us.
